Novartis Message Board - Msg: 13479484

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 122.63

+0.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark H. Bornfeld who wrote ()	4/22/2000 12:28:00 AM
From: Jack Hartmann	Read Replies (1) of 296

Novartis AG Gets FDA OK To Market Exelon Dow Jones Newswires EAST HANOVER, N.J. -- Novartis AG's (Z.NOV) Novartis Pharmaceuticals Corp. received Food and Drug Administration approval to market Exelon, a cholinesterase inhibitor for the treatment of patients with mild to moderate Alzheimer's disease. In a press release Friday, the company said Exelon is now cleared for marketing in nearly 70 countries. -Bill Platt; Dow Jones Newswires; 201-938-5400 ************** FDA been clearing alot lately. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next